In vitro results suggest that this response occurs via a rapid membrane–mediated signaling pathway that increases tumor growth and activates PLC and PKC to increase the production of osteoclast activating proteins RANKL and IL-6 to inhibit the production of OPG. This evidence concerns the gene TNFRSF11B and neoplasm.